Key facts
- This page summarizes Matthew K. Szot's Form 4 filing for Cadrenal Therapeutics, Inc. (CVKD).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 24 Jan 2025, 18:10.
Matthew K. Szot - 23 Jan 2025 Form 4 Insider Report for Cadrenal Therapeutics, Inc. (CVKD)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CVKD
- Reported as of
- 23 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jan 2025, 18:10:55 UTC
- Prior SEC filing
- 28 Aug 2024
- Next SEC filing
- 28 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew K. Szot
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Matthew K. Szot filed Form 4 for Cadrenal Therapeutics, Inc. (CVKD) on 24 Jan 2025.
Change
- Previous filing in this sequence was filed on 28 Aug 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CVKD
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 23 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $19.79
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Consists of options to purchase 50,000 shares of common stock, which shall vest 1/4 on February 1, 2026 and thereafter pro rata on a monthly basis over three years, subject to the Reporting Person's continued service to the Issuer through each vesting date, having an exercise price equal to the fair market value of the Issuer's common stock on the effective date of the grant.